CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.

Abstract:

BACKGROUND:Traditionally, following high-dose therapy (HDT), unmanipulated autologous PBPC are infused. Alternatively, purified CD34+ cells can now be obtained by immunomagnetic separation using the CliniMACS device. Limited data currently exist examining hemopoietic recovery with such cells. METHODS:Ten patients with advanced breast cancer had PBPC mobilized with docetaxel (100 mg/m2) and G-CSF (10 microg/kg per day), harvested and processed using the CliniMACS CD34-selection device and equally divided into three aliquots for cryopreservation. Unmanipulated 'back-up' cells were also collected on a separate day of the same mobilization, divided into three and cryopreserved. Patients subsequently received three cycles of HDT with cyclophosphamide (4 g/m2), thiotepa (300 mg/m2) and paclitaxel (175 mg/m2). The intent was for patients to receive CD34-selected cells to support each of the three cycles of HDT (i.e., 1/3 for each cycle). If, however, hemopoietic recovery was delayed after Cycle 1, 1/3 of the unmanipulated cells were infused following Cycle 2 and the remaining CD34-selected cells (2/3) were used to support Cycle 3. RESULTS:PBPC from 10 patients underwent CD34-selection with a resulting median purity of 93% (range: 76-98%) and yield of 62% (range: 16-93%). Of the 10 patients, only two were able to be supported with CD34-selected cells for all three cycles of HDT. The remaining eight patients required unmanipulated 'back-up' cells to support Cycle 2. Three patients also required infusion of 'back-up' unmanipulated cells because of persistent neutropenia (n = 1) or thrombocytopenia (n = 2) following cycles initially supported by CD34-selected cells. The median number of CD34-selected cells (x 10(6)/kg) infused per cycle was 1.5 (0.7-2.6) (n = 20) and unselected cells was 1.7 (1.4-2.8) (n = 10). Comparing hemopoietic recovery between cycles of HDT supported by CD34-selected (n = 20) and unmanipulated cells (n = 10) there was a significant slowing with the CD34-selected cells; time to ANC > 1.0 = 13 days versus 10 days, platelets > 20 = 17 days versus 13 days, > 50 = 25 versus 17 days (all P values < 0.001). There was no correlation between the dose of CD34-selected cells infused and neutrophil/platelet recovery. DISCUSSION:We have demonstrated that, although unmanipulated PBPC achieve rapid hemopoietic recovery (at modest CD34 doses of < or = 2.8 x 10(6)/kg), CliniMACS-selected CD34+ cells (in the doses utilized in this study of < or = 2.6 x 10(6)/kg) result in significantly prolonged recovery.

journal_name

Cytotherapy

journal_title

Cytotherapy

authors

Prince HM,Wall D,Rischin D,Toner GC,Seymour JF,Blakey D,Haylock D,Simmons P,Wolf M,Januszewicz EH,Westerman D,Richardson G,Scarlett J,Briggs P

doi

10.1080/146532402317381857

keywords:

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

147-55

issue

2

eissn

1465-3249

issn

1477-2566

pii

S1465-3249(02)71049-9

journal_volume

4

pub_type

临床试验,杂志文章
  • Expression and role of Toll-like receptors on human umbilical cord mesenchymal stromal cells.

    abstract:BACKGROUND AIMS:Toll-like receptors (TLRs) play an important role in innate and adaptive immunity by recognizing pathogen-associated molecular patterns (PAMPs). METHODS:In the present study, we investigated the expression and role of TLRs on human umbilical cord mesenchymal stromal cells (UC-MSCs). The proliferation, ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2012.12.001

    authors: Chen D,Ma F,Xu S,Yang S,Chen F,Rong L,Chi Y,Zhao Q,Lu S,Han Z,Pang A,Han Z

    更新日期:2013-04-01 00:00:00

  • Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.

    abstract:BACKGROUND AIMS:Adoptive transfer of tumor-infiltrating lymphocytes (TIL) has proven effective in metastatic melanoma and should therefore be explored in other types of cancer. The aim of this study was to examine the feasibility of potentially expanding clinically relevant quantities of tumor-specific T-cell cultures ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653249.2011.563291

    authors: Junker N,Andersen MH,Wenandy L,Dombernowsky SL,Kiss K,Sørensen CH,Therkildsen MH,Von Buchwald C,Andersen E,Straten PT,Svane IM

    更新日期:2011-08-01 00:00:00

  • Properties and growth of human bone marrow mesenchymal stromal cells cultivated in different media.

    abstract:BACKGROUND AIMS:Human mesenchymal stromal cells (hMSC) are a promising tool for future clinical application, but their use requires rapid cell expansion in media suitable for clinical use. Therefore, we tested the influence of several culture media on colony formation, population doubling (PD) time, cell cycle and surf...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653240903188947

    authors: Turnovcova K,Ruzickova K,Vanecek V,Sykova E,Jendelova P

    更新日期:2009-01-01 00:00:00

  • Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway.

    abstract:BACKGROUND AIMS:Imatinib (IM), a tyrosine kinase inhibitor targeting the BCR-ABL oncoprotein, remains a major therapeutic strategy for patients with chronic myelogenous leukemia (CML). However, IM resistance is still a challenge in the treatment of CML. Recently, it was reported that exosomes (Exo) were involved in dru...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2017.11.006

    authors: Liu Y,Song B,Wei Y,Chen F,Chi Y,Fan H,Liu N,Li Z,Han Z,Ma F

    更新日期:2018-02-01 00:00:00

  • TEMPORARY REMOVAL: CD271 identifies functional human hepatic stellate cells, which localize in peri-sinusoidal and portal areas in liver after partial hepatectomy.

    abstract:BACKGROUND AIMS:Hepatic stellate cells (HSCs) are liver-resident mesenchymal cells involved in essential processes in the liver. However, knowledge concerning these cells in human livers is limited because of the lack of a simple isolation method. METHODS:We isolated fetal and adult human liver cells by immunomagnetic...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2014.03.001

    authors: Patil PB,Joshi M,Kuna VK,Xu B,Johannesson L,Olausson M,Sumitran-Holgersson S

    更新日期:2014-07-01 00:00:00

  • In vitro cardiomyocyte differentiation of umbilical cord blood cells: crucial role for c-kit(+) cells.

    abstract:BACKGROUND AIMS:Although bone marrow c-kit(+) progenitor cells support myocardial regeneration, the cardiomyocyte differentiation potential of umbilical cord blood (UCB) c-kit(+) cells is unknown. METHODS:UCB mononuclear cells (MNCs) and c-kit(+) cells purified by use of immunomagnetic beads were used. Cardiomyocyte d...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.07.012

    authors: Iachininoto MG,Capodimonti S,Podda MV,Valentini CG,Bianchi M,Leone AM,Teofili L,Leone G

    更新日期:2015-11-01 00:00:00

  • Catastrophic failures of freezing bags for cellular therapy products: description, cause, and consequences.

    abstract:BACKGROUND:Container integrity is critical for maintaining sterility of cryopreserved cellular therapy products. We investigated a series of catastrophic bag failures, first noticed in early 2001. METHODS:Process records were reviewed for all PBPC and lymphocyte products cryopreserved in bags from January 2000 through...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/146532402761624700

    authors: Khuu HM,Cowley H,David-Ocampo V,Carter CS,Kasten-Sportes C,Wayne AS,Solomon SR,Bishop MR,Childs RM,Read EJ

    更新日期:2002-01-01 00:00:00

  • Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

    abstract:BACKGROUND AIMS:The Quantum® Cell Expansion System (Quantum; Terumo BCT, Inc, Lakewood, CO, USA) is a novel hollow fiber-based device that automates and closes the cell culture process, reducing labor intensive tasks such as manual cell culture feeding and harvesting. The manual cell selection and expansion processes f...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2013.05.024

    authors: Jones M,Varella-Garcia M,Skokan M,Bryce S,Schowinsky J,Peters R,Vang B,Brecheisen M,Startz T,Frank N,Nankervis B

    更新日期:2013-11-01 00:00:00

  • Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience.

    abstract:BACKGROUND AIMS:Corticosteroids are the standard first-line treatment for acute graft-versus-host disease (aGVHD), but they are associated with many complications, and less than half of patients have a sustained response. METHODS:To improve outcomes, we performed a retrospective study to analyze the efficacy of the ad...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2020.03.003

    authors: Sestili S,Eder S,Belhocine R,Dulery R,Battipaglia G,Brissot E,Mediavilla C,Banet A,van de Wyngaert Z,Paviglianiti A,Ledraa T,Bonin A,Mohty M,Malard F

    更新日期:2020-08-01 00:00:00

  • Implantation of BM mesenchymal stem cells into injured spinal cord elicits de novo neurogenesis and functional recovery: evidence from a study in rhesus monkeys.

    abstract:BACKGROUND:Transplantation of mesenchymal stem cells (MSC) in rodent models has proved to be an effective therapeutic approach for spinal cord injury (SCI). However, further studies in primate models are still needed before clinical application of MSC to patients. METHODS:MSC were isolated from rhesus monkey BM and in...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/14653240600760808

    authors: Deng YB,Liu XG,Liu ZG,Liu XL,Liu Y,Zhou GQ

    更新日期:2006-01-01 00:00:00

  • International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.

    abstract::Mesenchymal stromal cells (MSCs) as a pharmaceutical for ailments characterized by pathogenic autoimmune, alloimmune and inflammatory processes now cover the spectrum of early- to late-phase clinical trials in both industry and academic sponsored studies. There is a broad consensus that despite different tissue sourci...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.11.008

    authors: Galipeau J,Krampera M,Barrett J,Dazzi F,Deans RJ,DeBruijn J,Dominici M,Fibbe WE,Gee AP,Gimble JM,Hematti P,Koh MB,LeBlanc K,Martin I,McNiece IK,Mendicino M,Oh S,Ortiz L,Phinney DG,Planat V,Shi Y,Stroncek DF,Vi

    更新日期:2016-02-01 00:00:00

  • Species variation in the spontaneous calcification of bone marrow-derived mesenchymal stem cells.

    abstract::Bone marrow-derived mesenchymal stem cells (BM-MSCs) hold great promise for tissue regeneration. With increasing numbers of clinical trials, the safety of BM-MSCs attracts great interest. Previously, we determined that rat BM-MSCs possessed spontaneous calcification without osteogenic induction after continuous cultur...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2012.11.011

    authors: Huang YZ,Cai JQ,Lv FJ,Xie HL,Yang ZM,Huang YC,Deng L

    更新日期:2013-03-01 00:00:00

  • Hyperbaric oxygen treatment effects on in vitro cultured umbilical cord blood CD34+ cells.

    abstract:BACKGROUND AIMS:Umbilical cord blood (UCB) provides an alternative source for hematopoietic stem/progenitor cells (HSPCs) in the treatment of hematological malignancies. However, clinical usage is limited due to the low quantity of HSPCs in each unit of cord blood and defects in bone marrow homing. Hyperbaric oxygen (H...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2017.08.020

    authors: Cheung KY,Berry A,Li D,Aljitawi OS

    更新日期:2018-01-01 00:00:00

  • Is the subarachnoid administration of mesenchymal stromal cells a useful strategy to treat chronic brain damage?

    abstract:BACKGROUND AIMS:Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide. Developing effective protocols for the administration of mesenchymal stromal cells (MSCs) is a promising therapeutic strategy to treat TBI. It is important to develop alternatives to direct parenchymal injection at the...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2014.07.007

    authors: Bonilla C,Zurita M,Aguayo C,Rodríguez A,Vaquero J

    更新日期:2014-11-01 00:00:00

  • Transplantation of autologous rabbit BM-derived mesenchymal stromal cells embedded in hyaluronic acid gel sponge into osteochondral defects of the knee.

    abstract:BACKGROUND:Mesenchymal stromal cells (MSC) have the potential to differentiate into distinct mesenchymal tissues including cartilage, suggesting that these cells are an attractive cell source for cartilage tissue engineering approaches. Various methods, such as using hyaluronan-based materials, have been employed to im...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/14653240600845070

    authors: Kayakabe M,Tsutsumi S,Watanabe H,Kato Y,Takagishi K

    更新日期:2006-01-01 00:00:00

  • Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation.

    abstract:BACKGROUND:The use of myeloma Ag-loaded mature DC vaccines, cryopreserved in single-use aliquots, is an attractive immunotherapeutic strategy. In this study we investigated the retention of phenotype, viability and potency of DC vaccines after freezing and thawing. METHODS:Plastic-adherent monocytes, derived from a st...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/14653240510027235

    authors: Szmania S,Yi Q,Cottler-Fox M,Rosen NA,Freeman J,Kordsmeier BJ,Moreno A,Shi J,Barlogie B,Tricot G,van Rhee F

    更新日期:2005-01-01 00:00:00

  • Differentiated human adipose-derived stromal cells exhibit the phenotypic and functional characteristics of mature Schwann cells through a modified approach.

    abstract:BACKGROUND AIMS:Tissue engineering technology is a promising therapeutic strategy in peripheral nerve injury. Schwann cells (SCs) are deemed to be a vital component of cell-based nerve regeneration therapies. Many methods for producing SC-like cells derived from adipose-derived stromal cells (ADSCs) have been explored,...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2019.04.061

    authors: Kang Y,Liu Y,Liu Z,Ren S,Xiong H,Chen J,Duscher D,Machens HG,Liu W,Guo G,Zhan P,Chen H,Chen Z

    更新日期:2019-09-01 00:00:00

  • Decrease in circulating hematopoietic progenitor cells by trapping in the pulmonary circulation.

    abstract:BACKGROUND:When stem-cell grafts are infused into the venous circulation and stem/progenitor cells egress from BM, pulmonary capillary beds are the first microcirculation site that they encounter. This provides the potential for circulating progenitor cells to be trapped in the pulmonary circulation. METHODS:We compar...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/146532401317248063

    authors: Watanabe T,Kajiume T,Takaue Y,Kawano Y,Kanamaru S,Okamura S,Onishi T,Suzuya H,Nakagawa R,Kuroda Y,Talmadge JE

    更新日期:2001-01-01 00:00:00

  • Natural killer cell-based immunotherapeutic strategies.

    abstract::Not until recently have Natural killer (NK) cells stepped out of the shadow of T-cells to be considered for cellular therapy of malignant diseases. This evolution has been facilitated by the discovery of specific receptors on NK cells that interact with HLA molecules on target cells but also the discovery of specific ...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14653240510018000

    authors: Klingemann HG

    更新日期:2005-01-01 00:00:00

  • A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.

    abstract:BACKGROUND AIMS:Umbilical cord blood transplantation (UCBT) is increasingly used to treat acute leukemias. UCB units are thawed and infused in their entirety at transplant, precluding later use as immunotherapy to prevent or treat leukemia relapse. METHODS:We developed a device that selectively thaws only 1 mL of the ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.07.020

    authors: Vasu S,Berg M,Davidson-Moncada J,Tian X,Cullis H,Childs RW

    更新日期:2015-11-01 00:00:00

  • A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore.

    abstract::We report on a roundtable event hosted in Singapore that sought to identify some of the ethical and regulatory challenges in translating autologous cell-based interventions, particularly those claiming to involve stem cells, into safe and effective therapies and to propose some solutions to encourage responsible innov...

    journal_title:Cytotherapy

    pub_type:

    doi:10.1016/j.jcyt.2018.06.004

    authors: Lysaght T,Munsie M,Castricum A,Hui JHP,Okada K,Sato Y,Sawa Y,Stewart C,Tan LK,Tan LHY,Sugii S

    更新日期:2018-09-01 00:00:00

  • Mesenchymal stromal cell secretory factors induce sustained improvements in islet function pre- and post-transplantation.

    abstract:BACKGROUND AIMS:Mesenchymal stromal cells (MSCs) enhance islet function both in vitro and in vivo, at least in part by secreting ligands that activate islet G-protein coupled receptors (GPCRs). We assessed whether pre-treatment with a defined "cocktail" of MSC-secreted GPCR ligands enhances islet functional survival in...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2018.07.007

    authors: Rackham CL,Amisten S,Persaud SJ,King AJF,Jones PM

    更新日期:2018-12-01 00:00:00

  • Managing particulates in cellular therapy.

    abstract::he concept of particulates, while common to many in the pharmaceutical and blood transfusion disciplines, represents a distinct challenge in the field of cellular therapy. With newly discovered products advancing through clinical trials, the focus has shifted to ensuring products are manufactured in a reliable and saf...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.3109/14653249.2012.706709

    authors: Clarke D,Harati D,Martin J,Rowley J,Keller J,McCaman M,Carrion M,Karnieli O,Maziarz R,Perry R,Oh S,Stanton J

    更新日期:2012-10-01 00:00:00

  • Morphological profiling using machine learning reveals emergent subpopulations of interferon-γ-stimulated mesenchymal stromal cells that predict immunosuppression.

    abstract:BACKGROUND:Although a preponderance of pre-clinical data demonstrates the immunosuppressive potential of mesenchymal stromal cells (MSCs), significant heterogeneity and lack of critical quality attributes (CQAs) based on immunosuppressive capacity likely have contributed to inconsistent clinical outcomes. This heteroge...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2018.10.008

    authors: Marklein RA,Klinker MW,Drake KA,Polikowsky HG,Lessey-Morillon EC,Bauer SR

    更新日期:2019-01-01 00:00:00

  • Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy.

    abstract::Mesenchymal stromal cells (MSCs) are multipotent cells derived from various tissues that can differentiate into several cell types. MSCs are able to modulate the response of immune cells of the innate and adaptive immune system. Because of these multimodal properties, the potential use of MSCs for immunotherapies is c...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1016/j.jcyt.2017.03.076

    authors: de Wolf C,van de Bovenkamp M,Hoefnagel M

    更新日期:2017-07-01 00:00:00

  • HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.

    abstract:BACKGROUND:Identification of HLA class I-restricted CMV epitopes, and the subsequent synthesis of HLA class I-peptide tetrameric complexes, have provided investigators with an important tool for visualising and quantifying the precise in vivo CTL response to CMV reactivation following stem cell transplantation. In conj...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/146532402317251518

    authors: Chen FE,Aubert G,Travers P,Dodi IA,Madrigal JA

    更新日期:2002-01-01 00:00:00

  • A roadmap for cost-of-goods planning to guide economic production of cell therapy products.

    abstract::Cell therapy products are frequently developed and produced without incorporating cost considerations into process development, contributing to prohibitively costly products. Herein we contextualize individual process development decisions within a broad framework for cost-efficient therapeutic manufacturing. This roa...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1016/j.jcyt.2017.06.009

    authors: Lipsitz YY,Milligan WD,Fitzpatrick I,Stalmeijer E,Farid SS,Tan KY,Smith D,Perry R,Carmen J,Chen A,Mooney C,Fink J

    更新日期:2017-12-01 00:00:00

  • Good manufacturing practice-compliant validation and preparation of BM cells for the therapy of acute myocardial infarction.

    abstract:BACKGROUND:Intracoronary application of BM-derived cells for the treatment of acute myocardial infarction (AMI) is currently being studied intensively. Simultaneously, strict legal requirements surround the production of cells for clinical studies. Thus good manufacturing practice (GMP)-compliant collection and prepara...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/14653240601052734

    authors: Griesel C,Heuft HG,Herrmann D,Franke A,Ladas D,Stiehler N,Stucki A,Braun M,Wollert KC,Meyer GP,Drexler H,Hertenstein B,Ganser A,Rüdinger W,Arseniev L

    更新日期:2007-01-01 00:00:00

  • Secretomes from bone marrow-derived mesenchymal stromal cells enhance periodontal tissue regeneration.

    abstract:BACKGROUND AIMS:Periodontal tissue regeneration with the use of mesenchymal stromal cells (MSCs) has been regarded as a future cell-based therapy. However, low survival rates and the potential tumorigenicity of implanted MSCs could undermine the efficacy of cell-based therapy. The use of conditioned media from MSCs (MS...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2014.11.009

    authors: Kawai T,Katagiri W,Osugi M,Sugimura Y,Hibi H,Ueda M

    更新日期:2015-04-01 00:00:00

  • Ex vivo expansion of umbilical cord blood.

    abstract::The efficacy of cord blood (CB) transplantation is limited by the low cell dose available. Low cell doses at transplant are correlated with delayed engraftment, prolonged neutropenia and thrombocytopenia and elevated risk of graft failure. To potentially improve the efficacy of CB transplantation, approaches have been...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14653240510027172

    authors: Robinson S,Niu T,de Lima M,Ng J,Yang H,McMannis J,Karandish S,Sadeghi T,Fu P,del Angel M,O'Connor S,Champlin R,Shpall E

    更新日期:2005-01-01 00:00:00